Literature DB >> 19714336

Prognostic value of microvessel density in prostate cancer: a tissue microarray study.

Andreas Erbersdobler1, Hendrik Isbarn, Kira Dix, Isabel Steiner, Thorsten Schlomm, Martina Mirlacher, Guido Sauter, Alexander Haese.   

Abstract

PURPOSE: Angiogenesis is an important part in tumor progression and intratumoral microvessel density (MVD) has proven a prognostic factor in several solid tumors. However, its value in prostate cancer is still unclear, especially in small biopsy samples. We evaluated the prognostic potential of MVD in a large, homogeneous cohort of prostate cancers and its correlation with other pathologic parameters.
METHODS: We used a tissue microarray (TMA) containing samples of 3,261 prostatectomy specimens from patients with prostate cancer. MVD was determined by counting vessels in a blinded fashion after immunohistochemical staining with an antibody against CD31. The results were compared with pre- and postoperative clinical and pathological parameters and clinical follow-up data.
RESULTS: MVD was higher in TMA spots containing cancer as compared to benign tissue (P < 0.001). There was no significant correlation of MVD with preoperative parameters, but with pathological T-classification and Gleason score (P < 0.001, each) of the prostatectomy specimens. Furthermore, a higher MVD correlated with tumor location in the peripheral zone (P = 0.01). Follow-up data were available for 1,521 patients. In a univariable analysis, an MVD of ≥ 36 per spot was a significant predictor of PSA recurrence after radical prostatectomy (P = 0.03). However, it failed to provide an independent prognostic factor when combined with standard predictors in a multivariable analysis.
CONCLUSIONS: MVD in prostate cancer is closely related to other factors contributing to tumor aggressiveness. However, the implementation of this parameter into routinely performed pathological reports does not seem to be warranted.

Entities:  

Mesh:

Year:  2009        PMID: 19714336     DOI: 10.1007/s00345-009-0471-4

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  31 in total

Review 1.  Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999.

Authors:  D G Bostwick; D J Grignon; M E Hammond; M B Amin; M Cohen; D Crawford; M Gospadarowicz; R S Kaplan; D S Miller; R Montironi; T F Pajak; A Pollack; J R Srigley; J W Yarbro
Journal:  Arch Pathol Lab Med       Date:  2000-07       Impact factor: 5.534

Review 2.  Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies.

Authors:  L Bubendorf; A Nocito; H Moch; G Sauter
Journal:  J Pathol       Date:  2001-09       Impact factor: 7.996

Review 3.  Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.

Authors:  F E Harrell; K L Lee; D B Mark
Journal:  Stat Med       Date:  1996-02-28       Impact factor: 2.373

4.  Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments.

Authors:  M Mazumdar; J R Glassman
Journal:  Stat Med       Date:  2000-01-15       Impact factor: 2.373

5.  Independent association of angiogenesis index with outcome in prostate cancer.

Authors:  R Mehta; A Kyshtoobayeva; T Kurosaki; E J Small; H Kim; R Stroup; C E McLaren; K T Li; J P Fruehauf
Journal:  Clin Cancer Res       Date:  2001-01       Impact factor: 12.531

6.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

7.  Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer.

Authors:  D Strohmeyer; C Rössing; F Strauss; A Bauerfeind; O Kaufmann; S Loening
Journal:  Prostate       Date:  2000-01       Impact factor: 4.104

8.  Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: differences between tumours located in the transition zone and in the peripheral zone.

Authors:  Andreas Erbersdobler; Henning Fritz; Silvia Schnöger; Markus Graefen; Peter Hammerer; Hartwig Huland; R Peter Henke
Journal:  Eur Urol       Date:  2002-01       Impact factor: 20.096

9.  Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma.

Authors:  M T Gettman; A Pacelli; J Slezak; E J Bergstralh; M Blute; H Zincke; D G Bostwick
Journal:  Urology       Date:  1999-09       Impact factor: 2.649

10.  Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma.

Authors:  N Weidner; P R Carroll; J Flax; W Blumenfeld; J Folkman
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

View more
  43 in total

Review 1.  Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer.

Authors:  Tobias Franiel; Bernd Hamm; Hedvig Hricak
Journal:  Eur Radiol       Date:  2010-12-24       Impact factor: 5.315

2.  Assessment of prostate cancer with integrated CT-perfusion using a sector-wise approach.

Authors:  Matteo Ferrari; Martin Huellner; Chantal Pauli; Burkhardt Seifert; Hansjörg Danuser; Patrick Veit-Haibach; Agostino Mattei
Journal:  Turk J Urol       Date:  2017-05-03

3.  Microvessel density estimate: friend or foe in the light of prostate vascular system complexity?

Authors:  Gianluigi Taverna; Fabio Grizzi; Piergiuseppe Colombo; Pier Paolo Graziotti
Journal:  World J Urol       Date:  2010-01-21       Impact factor: 4.226

4.  Hepatoma-derived growth factor: a novel prognostic biomarker in intrahepatic cholangiocarcinoma.

Authors:  Sen Guo; Hong-da Liu; Yan-Feng Liu; Lei Liu; Qiang Sun; Xi-Jun Cui
Journal:  Tumour Biol       Date:  2014-09-28

5.  Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers.

Authors:  Henk van der Poel; Laurence Klotz; Gerald Andriole; Abdel-Rahmène Azzouzi; Anders Bjartell; Olivier Cussenot; Freddy Hamdy; Markus Graefen; Paolo Palma; Arturo Rodriguez Rivera; Christian G Stief
Journal:  World J Urol       Date:  2015-06-03       Impact factor: 4.226

Review 6.  Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management.

Authors:  Sadhna Verma; Baris Turkbey; Naira Muradyan; Arumugam Rajesh; Francois Cornud; Masoom A Haider; Peter L Choyke; Mukesh Harisinghani
Journal:  AJR Am J Roentgenol       Date:  2012-06       Impact factor: 3.959

7.  Dynamic contrast-enhanced magnetic resonance imaging in prostate cancer clinical trials: potential roles and possible pitfalls.

Authors:  Fiona M Fennessy; Rana R McKay; Clair J Beard; Mary-Ellen Taplin; Clare M Tempany
Journal:  Transl Oncol       Date:  2014-02-01       Impact factor: 4.243

8.  Feasibility study of CT perfusion imaging for prostate carcinoma.

Authors:  Nesat Cullu; Mecit Kantarci; Hayri Ogul; Senol Adanur; Aylin Okur; Erdem Koc; Berhan Pirimoglu; Leyla Karaca; Yesim Kizrak; Ozkan Polat
Journal:  Eur Radiol       Date:  2014-05-28       Impact factor: 5.315

9.  A direct comparison of contrast-enhanced ultrasound and dynamic contrast-enhanced magnetic resonance imaging for prostate cancer detection and prediction of aggressiveness.

Authors:  Alexander D J Baur; Julia Schwabe; Julian Rogasch; Andreas Maxeiner; Tobias Penzkofer; Carsten Stephan; Marc Rudl; Bernd Hamm; Ernst-Michael Jung; Thom Fischer
Journal:  Eur Radiol       Date:  2017-12-13       Impact factor: 5.315

Review 10.  Active surveillance for low-risk prostate cancer.

Authors:  Laurence Klotz
Journal:  Curr Urol Rep       Date:  2015-04       Impact factor: 3.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.